WaveBot: The Automated Trading Tool for This Bull Market

The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.

Alicia Grande Biography and Net Worth

CFO of Catalyst Pharmaceuticals

Alicia Grande, CPA, CMA, was appointed Vice President, Chief Financial Officer and Treasurer of Catalyst in December 2011, having joined the company as Corporate Controller and Chief Accounting Officer in 2007. Prior to that, she was Senior Director of Finance for The Hackett Group, Inc. (then known as Answerthink, Inc.), where she was responsible for all external and SEC financial reporting and served as head of the firm’s Sarbanes-Oxley Act compliance team. Ms. Grande previously was employed for more than 10 years by various public accounting firms, including Arthur Andersen, LLP. Ms. Grande earned a bachelor of science degree in business administration, with majors in accounting and finance, from Syracuse University and a master of accounting degree from Florida International University.

What is Alicia Grande's net worth?: The estimated net worth of Alicia Grande is at least $1.09 million as of December 8th, 2023. Ms. Grande owns 50,557 shares of Catalyst Pharmaceuticals stock worth more than $1,094,559 as of December 16th. This net worth approximation does not reflect any other assets that Ms. Grande may own. Learn More about Alicia Grande's net worth.
How do I contact Alicia Grande?: The corporate mailing address for Ms. Grande and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Alicia Grande's contact information.
Has Alicia Grande been buying or selling shares of Catalyst Pharmaceuticals?: Alicia Grande has not been actively trading shares of Catalyst Pharmaceuticals over the course of the past ninety days. Most recently, Alicia Grande sold 60,000 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $13.76, for a transaction totalling $825,600.00. Following the completion of the sale, the chief financial officer now directly owns 50,557 shares of the company's stock, valued at $695,664.32. Learn More on Alicia Grande's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 440,755 shares worth more than $8,352,888.44. The most recent insider tranaction occured on December, 10th when insider Steve Miller sold 50,000 shares worth more than $1,096,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 12/10/2024.

Alicia Grande Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2023	Sell	60,000	$13.76	$825,600.00	50,557
12/8/2023	Sell	40,000	$14.28	$571,200.00	50,557
3/28/2023	Sell	58,216	$16.54	$962,892.64	50,557
3/22/2023	Sell	41,784	$16.50	$689,436.00	50,557
11/22/2022	Sell	120,000	$16.53	$1,983,600.00	27,442
11/15/2022	Sell	60,000	$15.77	$946,200.00	147,442
9/23/2022	Sell	60,000	$11.90	$714,000.00	207,442
9/16/2022	Sell	90,000	$13.50	$1,215,000.00	267,442
9/14/2022	Sell	50,000	$15.57	$778,500.00	357,442
8/29/2022	Sell	57,000	$14.20	$809,400.00	407,442
8/26/2022	Sell	11,095	$14.40	$159,768.00	464,442
8/17/2022	Sell	130,741	$13.86	$1,812,070.26	475,537
8/17/2021	Sell	100,000	$5.67	$567,000.00	507,441

Alicia Grande Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.65

$21.33

$22.03

50 Day Range

MA: $21.65

$19.91

$23.93

2 Week Range

Now: $21.65

$13.12

$24.27

Volume

722,412 shs

Average Volume

1,167,456 shs

Market Capitalization

$2.58 billion

P/E Ratio

18.35

Dividend Yield

N/A

Beta

0.75